The Latest Breaking News from PFE

The far-right Patriots for Europe are now a step closer to derail one of the EU’s flagship policy, the so-called Green Deal.

Seemingly undervalued dividend stocks, such as BAC, F, MO, VZ, and PFE, offer a rare combination of strong yields and attractive valuations.

Large unusual trading volume in Pfizer put options that expire 30 days from now signals investors' bullish outlook on PFE stock. It trades for just over 8 times earnings, well below its 10-year historical average P/E ratio.

Pfizer has underperformed the S&P 500 over the past year, but analysts are moderately optimistic about the stock’s prospects.

The three Polish members of Europe of Sovereign Nations are unhappy with the group’s stance on Russia. But they will not leave it (for now).

Pfizer has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.

Amid the continued decline in Pfizer stock, its dividend yield has risen to almost 8%. While the stock might not be a screaming buy, it now seems to have limited downside.

Pfizer will release its first-quarter earnings later this month, and analysts anticipate a double-digit profit dip.

Large, unusual trading volume in Pfizer put options is accruing today, signaling a bearish outlook by institutional investors in PFE stock. This undoubtedly relates to the Chinese tariffs, and investors' concerns.

Pfizer has underperformed the pharmaceuticals industry over the past year, but analysts are moderately optimistic about the stock’s prospects.

The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI), propelling the industry’s growth. Amid this backdrop, quality medical stocks Pfizer (PFE), AstraZeneca (AZN), and Novartis (NVS), which are transforming medicine with AI-powered drug discovery, could be ideal portfolio additions. Continue reading.